Developing tools to enhance T cell responses against cancer and infections
Mechano-ID for tagging immune cells
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-10987031
This study is exploring new ways to help T cells, which are important for fighting cancer and infections, recognize and respond better to harmful cells, with the hope of improving treatments for cancer and autoimmune diseases.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10987031 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative tools to better understand how T cells, a crucial part of the immune system, recognize and respond to cancer cells and pathogens. By studying the mechanical forces involved in the interaction between T cells and target cells, the researchers aim to improve the effectiveness of T cell activation. The project will utilize advanced techniques to tag T cells based on these mechanical interactions, which could lead to more accurate predictions of how well T cells can respond to specific threats in the body. This approach may ultimately enhance the development of targeted immunotherapies for cancer and autoimmune diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults over 21 years old who are undergoing treatment for cancer or have autoimmune disorders.
Not a fit: Patients with non-cancerous conditions or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies that improve patient outcomes in cancer treatment and autoimmune conditions.
How similar studies have performed: Other research has shown promising results using mechanical force-based approaches to enhance T cell activation, indicating that this method has potential for success.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SALAITA, KHALID S. — EMORY UNIVERSITY
- Study coordinator: SALAITA, KHALID S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy